Telix Pharmaceuticals Limited

NasdaqGS:TLX Stock Report

Market Cap: US$3.5b

Telix Pharmaceuticals Management

Management criteria checks 3/4

Telix Pharmaceuticals' CEO is Chris Behrenbruch, appointed in Jul 2023, has a tenure of 2.75 years. total yearly compensation is $1.26M, comprised of 44.1% salary and 55.9% bonuses, including company stock and options. directly owns 6.41% of the company’s shares, worth $225.15M. The average tenure of the management team and the board of directors is 3 years and 8.2 years respectively.

Key information

Chris Behrenbruch

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage44.13%
CEO tenure2.8yrs
CEO ownership6.4%
Management average tenure3yrs
Board average tenure8.2yrs

Recent management updates

Recent updates

Telix Pharmaceuticals: Solid Q1 As Pipeline And PSMA Franchise Drive Outlook

Apr 08

Telix Pharmaceuticals: Australian Company And A Solid Recent U.S. IPO

Dec 26

CEO Compensation Analysis

How has Chris Behrenbruch's remuneration changed compared to Telix Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$1mUS$557k

-US$7m

Sep 30 2025n/an/a

US$2m

Jun 30 2025n/an/a

US$11m

Mar 31 2025n/an/a

US$19m

Dec 31 2024US$929kUS$400k

US$34m

Sep 30 2024n/an/a

US$34m

Jun 30 2024n/an/a

US$33m

Mar 31 2024n/an/a

US$21m

Jan 01 2024n/an/a

US$4m

Sep 30 2023n/an/a

-US$14m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$589kUS$288k

-US$71m

Sep 30 2022n/an/a

-US$71m

Jun 30 2022n/an/a

-US$82m

Mar 31 2022n/an/a

-US$75m

Dec 31 2021US$451kUS$272k

-US$58m

Sep 30 2021n/an/a

-US$50m

Jun 30 2021n/an/a

-US$44m

Mar 31 2021n/an/a

-US$39m

Dec 31 2020US$325kUS$228k

-US$35m

Sep 30 2020n/an/a

-US$29m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$20m

Dec 31 2019US$323kUS$222k

-US$20m

Compensation vs Market: Chris's total compensation ($USD1.26M) is below average for companies of similar size in the US market ($USD6.93M).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Behrenbruch (49 yo)

2.8yrs
Tenure
US$1,261,658
Compensation

Dr. Christian P. Behrenbruch, also known as Chris, BEng (Hons), J.D., Ph.D. DPhil (Oxon), MBA (TRIUM), JD (Melb), FIEAust, GAICD, is Co-Founder, Chief Executive Officer and Managing Director of Telix Pharm...

Leadership Team

NamePositionTenureCompensationOwnership
Christian Behrenbruch
Co-Founder2.8yrsUS$1.26m6.41%
$ 225.2m
Darren Smith
Group Chief Financial Officer3.7yrsUS$1.02m0.0035%
$ 123.6k
Darren Patti
Group Chief Operating Officer2.1yrsUS$849.25k0.0078%
$ 273.2k
David Cade
Group Chief Medical Officer2.3yrsUS$545.20k0.11%
$ 3.9m
Paul Schaffer
SVP of Research & Development1yrno datano data
Craig Ulrick
Chief Information Officer3.3yrsno datano data
Kyahn Williamson
Senior Vice President of Corporate Communications & Investor Relations4.8yrsno datano data
Christian Krautkramer
Group General Counselless than a yearno datano data
Thomas Fromm
Vice President of Salesno datano datano data
Meredith Crowe
Senior Vice President of Global People & Culture3.6yrsno datano data
Andreas Kluge
Chief Medical Advisorno dataUS$68.78k6.69%
$ 235.0m
Odile Jaume
Advisor6.2yrsno datano data
3.0yrs
Average Tenure
55yo
Average Age

Experienced Management: TLX's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christian Behrenbruch
Co-Founder9.3yrsUS$1.26m6.41%
$ 225.2m
Chaitanya Divgi
Member of the Scientific Advisory Boardno datano datano data
Rodney Hicks
Member of the Scientific Advisory Boardno datano datano data
Neil Bander
Member of the Scientific Advisory Boardno datano datano data
Mark Nelson
Interim Independent Non-Executive Chair8.6yrsUS$129.52k1.07%
$ 37.6m
Jann Skinner
Independent Non-Executive Director7.8yrsUS$150.84k0.18%
$ 6.2m
Jean-François Chatal
Member of the Scientific Advisory Boardno datano datano data
Marie McDonald
Independent Non-Executive Director1.1yrsUS$116.65k0.0011%
$ 38.6k
Jason Lewis
Member of the Scientific Advisory Boardno datano datano data
Klaus Kopka
Member of the Scientific Advisory Boardno datano datano data
Samuel Samnick
Member of the Scientific Advisory Boardno datano datano data
Richard Baum
Member of the Scientific Advisory Boardno datano datano data
8.2yrs
Average Tenure
65.5yo
Average Age

Experienced Board: TLX's board of directors are considered experienced (8.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/10 01:57
End of Day Share Price 2026/04/10 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Telix Pharmaceuticals Limited is covered by 21 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Melissa BensonBarrenjoey Markets Pty Limited
John HesterBell Potter
Shane StoreyCanaccord Genuity